Double-blind, randomized, placebo-controlled trial of allergen-specific immunotherapy with the major allergen Alt a1
NAGIOS: RODERIC FUNCIONANDO

Double-blind, randomized, placebo-controlled trial of allergen-specific immunotherapy with the major allergen Alt a1

DSpace Repository

Double-blind, randomized, placebo-controlled trial of allergen-specific immunotherapy with the major allergen Alt a1

Show simple item record

dc.contributor.author Tabar, Ana Isabel
dc.contributor.author Prieto, Luis
dc.contributor.author Alba, Pilar
dc.contributor.author Nieto, Antonio
dc.contributor.author Rodríguez, Mercedes
dc.contributor.author Torrecillas, Miguel
dc.contributor.author Huertas, Beatriz
dc.contributor.author Gómez, Elisa
dc.contributor.author Fernández, Francisco Javier
dc.contributor.author Blanca, Miguel
dc.contributor.author Rodríguez, David
dc.contributor.author Palacios, Ricardo
dc.date.accessioned 2021-03-09T08:19:33Z
dc.date.available 2021-03-09T08:19:33Z
dc.date.issued 2019
dc.identifier.uri https://hdl.handle.net/10550/78206
dc.description.abstract Background: There have been fewstudies conducted on the efficacy and safety of specific immunotherapy with allergen extracts of fungi compared with other allergen extracts, and there are no data on the major allergen Alt a 1 of the fungus Alternaria alternata. Objectives: We sought to evaluate the efficacy and safety of subcutaneous immunotherapy with 2 different doses of Alt a 1 in patients with rhinoconjunctivitis caused by sensitization to A alternata. Method: We performed a multicenter, randomized, doubleblind, placebo-controlled trial with Alt a 1 administered subcutaneously in patients with allergic rhinoconjunctivitis with or without controlled asthma aged 12 to 65 years. Three groups were included: the placebo group and active groups receiving 0.2 or 0.37 mg of Alt a 1 per dose. The main end point was the combined symptom and medication score. Secondary end points were cutaneous reactivity and serum IgE and IgG4 levels to Alta 1. Recorded adverse reactions were graded according to World Allergy Organization criteria. Results: There were significant reductions in the combined symptom and medication score for the 0.37-mg dose of Alt a 1 compared with placebo at 12 months of treatment. Reduced cutaneous reactivity and IgE levels, together with increased IgG4 levels, were demonstrated for the 2 active groups versus the placebo group. A similar safety profile was found for both active groups compared with the placebo group. No serious adverse drug reactions were reported. Conclusion: Immunotherapy with Alt a 1 was efficacious and safe, reducing the symptoms and medication consumption associated with rhinoconjunctivitis after only 1 year of treatment. The clinical benefits were associated with reduced skin reactivity and specific IgE levels and increased IgG4 levels.
dc.language.iso eng
dc.relation.ispartof Journal of Allergy and Clinical Immunology, 2019, vol. 144, num. 1, p. 216-223
dc.rights.uri info:eu-repo/semantics/openAccess
dc.source Tabar, Ana Isabel Prieto, Luis Alba, Pilar Nieto, Antonio Rodríguez, Mercedes Torrecillas, Miguel Huertas, Beatriz Gómez, Elisa Fernández, Francisco Javier Blanca, Miguel Rodríguez, David Palacios, Ricardo 2019 Double-blind, randomized, placebo-controlled trial of allergen-specific immunotherapy with the major allergen Alt a1 Journal of Allergy and Clinical Immunology 144 1 216 223
dc.subject Al·lèrgia
dc.title Double-blind, randomized, placebo-controlled trial of allergen-specific immunotherapy with the major allergen Alt a1
dc.type info:eu-repo/semantics/article
dc.date.updated 2021-03-09T08:19:33Z
dc.identifier.idgrec 143662

View       (1.413Mb)

This item appears in the following Collection(s)

Show simple item record

Search DSpace

Advanced Search

Browse

Statistics